Global Radiopharmaceuticals in Nuclear Medicine Industry Growth and Trends Forecast to 2031

Summary

According to APO Research, The global Radiopharmaceuticals in Nuclear Medicine market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals in Nuclear Medicine.

The Radiopharmaceuticals in Nuclear Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radiopharmaceuticals in Nuclear Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
Novartis
SIEMENS
Bayer
Dongcheng
Eli Lilly
China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology
Cardiology
Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2020-2031)
1.3 Radiopharmaceuticals in Nuclear Medicine Market by Type
1.3.1 Diagnostic Radiopharmaceuticals
1.3.2 Therapy Radiopharmaceuticals
1.4 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Overview by Type (2020-2031)
1.4.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size Review by Type (2020-2025)
1.4.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2020-2025)
1.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2020-2025)
1.5.4 South America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Revenue (2020-2025)
3.2 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Sales (2020-2025)
3.3 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Price (2020-2025)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Radiopharmaceuticals in Nuclear Medicine Major Company Production Sites & Headquarters
3.6 Global Radiopharmaceuticals in Nuclear Medicine Company, Product Type & Application
3.7 Global Radiopharmaceuticals in Nuclear Medicine Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue in 2024
3.8.3 2023 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3
4 Radiopharmaceuticals in Nuclear Medicine Regional Status and Outlook
4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Region
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2020-2025)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2020-2025)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Region
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2026-2031)
4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2026-2031)
4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Radiopharmaceuticals in Nuclear Medicine by Application
5.1 Radiopharmaceuticals in Nuclear Medicine Market by Application
5.1.1 Oncology
5.1.2 Cardiology
5.1.3 Other
5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Overview by Application (2020-2031)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size Review by Application (2020-2025)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2020-2025)
5.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2020-2025)
5.3.4 South America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Aurobindo Pharma
6.1.1 Aurobindo Pharma Comapny Information
6.1.2 Aurobindo Pharma Business Overview
6.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.1.5 Aurobindo Pharma Recent Developments
6.2 Bracco Imaging
6.2.1 Bracco Imaging Comapny Information
6.2.2 Bracco Imaging Business Overview
6.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.2.5 Bracco Imaging Recent Developments
6.3 Cardinal Health
6.3.1 Cardinal Health Comapny Information
6.3.2 Cardinal Health Business Overview
6.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.3.5 Cardinal Health Recent Developments
6.4 Curium Pharma
6.4.1 Curium Pharma Comapny Information
6.4.2 Curium Pharma Business Overview
6.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.4.5 Curium Pharma Recent Developments
6.5 GE Healthcare
6.5.1 GE Healthcare Comapny Information
6.5.2 GE Healthcare Business Overview
6.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.5.5 GE Healthcare Recent Developments
6.6 Jubilant Pharma
6.6.1 Jubilant Pharma Comapny Information
6.6.2 Jubilant Pharma Business Overview
6.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.6.5 Jubilant Pharma Recent Developments
6.7 Lantheus
6.7.1 Lantheus Comapny Information
6.7.2 Lantheus Business Overview
6.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.7.5 Lantheus Recent Developments
6.8 Mundipharma
6.8.1 Mundipharma Comapny Information
6.8.2 Mundipharma Business Overview
6.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.8.5 Mundipharma Recent Developments
6.9 Novartis
6.9.1 Novartis Comapny Information
6.9.2 Novartis Business Overview
6.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.9.5 Novartis Recent Developments
6.10 SIEMENS
6.10.1 SIEMENS Comapny Information
6.10.2 SIEMENS Business Overview
6.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.10.5 SIEMENS Recent Developments
6.11 Bayer
6.11.1 Bayer Comapny Information
6.11.2 Bayer Business Overview
6.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.11.5 Bayer Recent Developments
6.12 Dongcheng
6.12.1 Dongcheng Comapny Information
6.12.2 Dongcheng Business Overview
6.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.12.5 Dongcheng Recent Developments
6.13 Eli Lilly
6.13.1 Eli Lilly Comapny Information
6.13.2 Eli Lilly Business Overview
6.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.13.5 Eli Lilly Recent Developments
6.14 China Isotope & Radiation
6.14.1 China Isotope & Radiation Comapny Information
6.14.2 China Isotope & Radiation Business Overview
6.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.14.5 China Isotope & Radiation Recent Developments
7 North America by Country
7.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country
7.1.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
7.1.3 North America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2026-2031)
7.2 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
7.2.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country (2020-2025)
7.2.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
8.1.3 Europe Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2026-2031)
8.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country
8.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country (2020-2025)
8.2.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country
9.1.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
9.1.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Country
9.2.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country
10.1.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
10.1.3 South America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2026-2031)
10.2 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
10.2.1 South America Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Country (2020-2025)
10.2.3 South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country
11.1.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
11.1.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country
11.2.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
12.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
12.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
12.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings